Diafir will be present at the next Bio-Europe convention which will take place in Copenhagen from 5 to 7 November 2018. The 24th edition of BIO-Europe is Europe’s largest partnership conference serving the global biotechnology sector. This year’s BIO-Europe Partnership Event will bring together more than 4,000 participants from more than 60 countries, representing more […]
Breakthrough serum diagnostic for NASH and other diseases
French Photonic Day
Bercy, Ministry of Industry
Mid-infrared light biosensor
Where mid-infrared spectroscopy meets medicine
DIAFIR will be present from 3 to 6 October in Lyon at the scientific days of the AFEF (French Society for the Study of the Liver).
DIAFIR has been incepted in 2011 by a world-renowned team of researchers from Rennes 1 University, France.
DIAFIR has developed the SPID™ platform, a breakthrough proprietary device for patient screening triage. SPID™ analyses the entire metabolic signature spectrum of patient’s blood serum, within minutes, using mid-infrared spectroscopy.
Thanks to its platform, DIAFIR aims to develop and bring to market its revolutionary serum test NASHMIR® for NASH detection.
Our goal is to help save lives through early detection while being minimally invasive to the patient.
- DIAFIR’s vision is to become the standard of care in the way people are routinely checked for NASH (early detection).
- DIAFIR’s method is easy to implement and at a low cost, currently targeting the obese patients as the first choice for NASH detection.
- Our proprietary platform SPID™ can be applied on other types of diseases (as a start we are focused on NASH and infectious arthropathies).